NEW YORK and BERLIN, Sept. 04, 2024 —  (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the H.C. Wainwright 26^th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company’s participation are as follows:

Format: Fireside chat and 1×1 investor meetings
Date and Time: Fireside chat on Tuesday, September 10 at 4:30 P.M. EDT
Webcast link:

An archived replay will be available on the Investors section of the atai website under  for up to 90 days.

About atai Life Sciences

atai is a clinical-stage biopharmaceutical company that is focused on transforming the treatment of mental health disorders. The company was founded in response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients. atai’s vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit .

Contact Information

Investor Contact:

Media Contact: